Cargando…
EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
BACKGROUND: EGFR/c-Met activation/amplification and co-expression, mTOR upregulation/activation, and Akt/Wnt signaling upregulation have been individually associated with more aggressive disease and characterized as potential prognostic markers for lung cancer patients. METHODS: Tumors obtained from...
Autores principales: | Crees, Zachary D, Shearrow, Caleb, Lin, Leo, Girard, Jennifer, Arasi, Kavin, Bhoraskar, Aayush, Berei, Joseph, Eckburg, Adam, Anderson, Austin D., Garcia, Christian, Munger, Ariana, Palani, Sunil, Smith, Thomas J, Sreenivassappa, Shylendra B, Vitali, Connie, David, Odile, Puri, Neelu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493230/ https://www.ncbi.nlm.nih.gov/pubmed/32973931 http://dx.doi.org/10.1177/1758835920953731 |
Ejemplares similares
-
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020) -
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020) -
Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer
por: Ren, Yijiu, et al.
Publicado: (2020) -
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
por: Frost, Nikolaj, et al.
Publicado: (2021) -
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
por: Illini, Oliver, et al.
Publicado: (2021)